Title |
Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches
|
---|---|
Published in |
Supportive Care in Cancer, December 2013
|
DOI | 10.1007/s00520-013-2098-7 |
Pubmed ID | |
Authors |
Julian Lindsay, Michael Dooley, Jennifer Martin, Michael Fay, Alison Kearney, Michael Barras |
Abstract |
Cancer patients who have transitioned from curative intent chemotherapy or radiotherapy to palliative therapy have limited life expectancies. Due to this, medications for primary and secondary prevention or those with no short-term benefit are potentially inappropriate medicines in this patient group. These medications often have potentially harmful profiles, increasing the patient's adverse drug events, pill burden, and medication costs. This review evaluates the most current evidence to assess the outcomes and potential methods used for identifying and ceasing potentially inappropriate medications (PIMs) in palliative cancer patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 20% |
Saudi Arabia | 1 | 20% |
Portugal | 1 | 20% |
United Kingdom | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Finland | 1 | <1% |
Unknown | 146 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 20 | 14% |
Researcher | 19 | 13% |
Student > Bachelor | 17 | 11% |
Other | 16 | 11% |
Student > Ph. D. Student | 15 | 10% |
Other | 35 | 24% |
Unknown | 26 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 58 | 39% |
Pharmacology, Toxicology and Pharmaceutical Science | 31 | 21% |
Nursing and Health Professions | 15 | 10% |
Agricultural and Biological Sciences | 3 | 2% |
Social Sciences | 3 | 2% |
Other | 7 | 5% |
Unknown | 31 | 21% |